Neoleukin Therapeutics (NASDAQ:NLTX) Trading Up 4.5%

Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) traded up 4.5% during mid-day trading on Friday . The stock traded as high as $37.15 and last traded at $36.39. 1,535,179 shares traded hands during trading, an increase of 2,964% from the average session volume of 50,104 shares. The stock had previously closed at $34.82.

Neoleukin Therapeutics Trading Up 4.5 %

The company has a market cap of $341.99 million, a P/E ratio of -11.70 and a beta of 1.11. The business’s fifty day moving average is $34.03 and its 200 day moving average is $32.04.

Institutional Investors Weigh In On Neoleukin Therapeutics

A hedge fund recently bought a new stake in Neoleukin Therapeutics stock. Adage Capital Partners GP L.L.C. bought a new stake in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 310,000 shares of the company’s stock, valued at approximately $1,224,000. Adage Capital Partners GP L.L.C. owned about 3.52% of Neoleukin Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.